An-Dinh Nguyen interviews Brian Chadwick of LookLeft Group LLC on September 10, 2013. Mr. Chadwick will be speaking during the Business of Running a Biobank session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN.

Topics include regulatory compliance challenges of biospecimen management, software solutions, commercial vs. nonprofit biobanks, patient rights and more.

BioBanking Podcast | Sample Acquisition and Management: Biobanking Regulations and Improvements

Kip Harry interviews Dr. David Smith from the Mayo Clinic, and Dr. Melanie Lehman from Queensland University of Technology for the upcoming RNA-Seq and Transcriptome Analysis meeting, 5-6 December in Lisbon, Portugal. 

Discussion points during the interview include:

•	The advantages of using RNA-Seq for expression analysis over microarrays
•	The impact of RNA-Seq on research and recent advances in the applications of this technology
•	Ways in which RNA-Seq is being utilized clinically
•	Current challenges/limitations with RNA-Seq


Clinical Genomics Podcast | The Importance of RNA-Sequencing

Amid Zand Interview Dr. Sundos Hamza of InterMune on December 12, 2014. In this interview Dr. Hamza speaks about the importance of effective global drug safety risk minimization strategies in clinical and post marketing phases of drug development.

SCOPE 2015 | Managing Drug Safety Challenges from Clinical Trials to Post Marketing Stages

David Barton will discuss the new regulations being developed, which have major implications for IVD manufacturers and for laboratory-developed tests. This podcast will give an overview of the proposed new IVD regulation, a timeline for development, and briefly discuss how it will impact IVD manufacturers and clinical labs.

MDXE 2015 | How Will the New Regulation Change the IVD Landscape in Europe

CHI sits down with Dr. Mike Makrigiorgos of Dana Farber and Brigham to discuss a new COLD-PCR method (temperature tolerant COLD-PCR) that uses targeted re-sequencing to detect mutations as low as .01-.1%. In this podcast, Dr. Makrigiorgos discusses the science behind COLD PCR, gives a preview of his talk at the April cfDNA conference in Lisbon, and discusses the future impact of liquid biopsy.

Molecular DX Europe 2015 | COLD-PCR for Liquid Biopsy: Current Impact and Future Directions

CHI interviews Dr. Claudio Hetz, Professor in the Institute of Biomedical Sciences, and Principal Investigator in the Laboratory of Cellular Stress and Biomedicine at the University of Chile about the rapidly evolving drug discovery space of targeting the unfolded protein response (UPR) - particularly for cancers and neurodegenerative diseases.
 
Discussion questions include:
•	Why has targeting components of the UPR emerged as a viable therapeutic strategy? (What are some of the recent critical discoveries that have propelled this field forward?)

•	What are emerging and promising therapeutic targets within the UPR and why?

•	What are some of the current challenges surrounding targeting the UPR?

•	You are giving a lecture during the upcoming Targeting the Unfolded Protein Response meeting, September 23-24 in Boston. Can you tell us a little about your work and what you hope to convey to attendees during the conference?

•	What are people within this space just now starting to think about? In other words, where will the greatest attention be over the next few years within this space?

To learn more, visit http://www.DiscoveryOnTarget.com/

Discovery on Target 2015 | Targeting The Unfolded Protein Response

Romney Humphries, Assistant Professor, UCLA Pathology & Laboratory Medicine, Section Chief of Clinical Microbiology, David Geffen School of Medicine, University of California, Los Angeles spoke to CHI to discuss how Next-Generation Sequencing has changed the way scientists detect antimicrobial resistance as well as the challenges scienctists face moving forward.

Dr. Humprhies is one of our speakers at the Molecular Diagnostics for Infectious Disease conference, taking place March 7-9 as part of the Molecular Medicine TriConference. For details, visit http://www.TriConference.com/Molecular-Diagnostics-for-Infectious-Disease/


Molecular Med Tri-Con 2016 | Next-Generation Sequencing for Detecting Antimicrobial Resistance

Tom Lawler, Founder & Managing Partner, BaywynSolutions spoke to CHI to discuss the role of teamwork in outsourcing relationships for clinical trials and some of the tangible challenges, delays, and errors that can come from teams lacking a collaborative framework. He also discusses some metrics groups can use to measure their success in their outsourced relationships.
 
Tom is speaking at Outsourcing for Clinical Trials, taking place April 25-26, 2017 in Boston as part of the Clinical Trial Innovation Summit. For details, visit: http://www.ClinicalTrialSummit.com/Clinical-Outsourcing/

Clinical Trial Innovation Summit 2017 | The Need for Collaboration and Performance Metrics

Aidan Synnott of Charles River Laboratories speaks to CHI on May 3, 2017. Charles River Laboratories will be speaking during the Preclinical Models and Tools in Oncology - Part 1
and Tumor Models for Cancer Immunotherapy - Part 2, June 13-15,2017 in Boston, MA.
 
Topics include overcoming challenges for cancer therapeutics, CAR-T cells, combination therapies and advice for drug companies looking to work with CROs

For more information, please visit http://www.WorldPreclinicalCongress.com/Cancer-Models/ and http://www.WorldPreclinicalCongress.com/Tumor-Models-Immunotherapy/

World Preclinical Congress 2017 | Cancer Therapeutics – Advice for the Future

Alexis Sauer-Budge of Fraunhofer CMI and Boston University speaks to CHI on May 9, 2017. Dr. Sauer-Budge will be speaking during the Sample Preparation Track at the Biodefense World Summit, June 26-29, 2017, in Alexandria, VA.

Traditionally, bacterial pathogens have been identified using culture-based methods that can take several days to obtain results. This can lead to physicians making treatment decisions based on an incomplete diagnosis. To decrease diagnosis time, we are developing novel devices and methods for isolating, concentrating, and detecting dilute viable pathogens and coupling these with novel downstream detection modalities.

Biodefense World Summit 2017 | Empowering Rapid Diagnostics with Sample Preparation Methodologies

CHI interviews Dr. Craig Crews, Professor of Molecular, Cellular and Developmental Biology, Chemistry and Pharmacology at Yale University. Dr. Crews tells the story of the birth and evolution of PROTACs, provides commentary on preclinical challenges, and provides his outlook for continued development.  
 
Discussion and Questions Include:

•	The ability to target components of the Ubiquitin Proteasome System with bifunctional PROTACs molecules has recently generated significant interest within the drug discovery community. Can you share with us a bit about the history and progression of this new mode of drug action?
•	There are several commercial entities currently working on a new generation of bifunctional molecules, including Arvinas, a biotech you’ve founded. Can you discuss some of the current challenges surrounding this approach during pre-clinical development?
•	You are chairing a session and giving a keynote address during the upcoming Targeting the Ubiquitin Proteasome System conference, September 26-27 in Boston. Can you share with us a bit on what you hope to convey during the session and keynote lecture?
•	We would like your opinion on the future of PROTACs – which appears to be very promising. We’ve talked about some of the current challenges, but can you share with us how you are working to address and overcome these challenges for continued development?

For more information, please visit http://www.DiscoveryOnTarget.com/Ubiquitin-Proteasome/

Discovery on Target 2017 - PROTACs: The Chemical Equivalent of CRISPR

Tauseef Butt, CEO of Progenra Inc. speaks to CHI on September 8, 2017. Dr. Butt will be presenting during Immunomodulatory Small Molecules and Targeting the Ubiquitin Proteasome System, taking place this September 27-28 at Discovery on Target in Boston, MA.

Topics include the benefits and challenges of immunomodulatory small molecules, Ubiquitin Protease (USP7) Inhibitors performance in animal models, Progenra’s discovery platform and their plans for developing other immunomodulatory strategies.

Discovery on Target 2017 | Small Molecule Ubiquitin Protease (USP7) Inhibitors

Dr. Wells, Professor of Pharmaceutical Chemistry at the University of California, San Francisco, shares insights about his upcoming and the keynote presentation in the Emerging Technologies for Antibody Discovery conference being held on January 11th and 12th at PepTalk.

For more information, please visit http://www.CHI-PepTalk.com/Antibody-Discovery/

PepTalk 2018 | Remodeling of Cell Surfaceomes in Cancer

Débora Araujo of Boehringer Ingelheim spoke to CHI to discuss her expertise in clinical trial agreements and some of the daily challenges she faces in negotiations and contracts. She specifically discusses some of the key barriers within and beyond the legal language of CTAs and also shares highlights from her forthcoming book, The Four Villains of Clinical Trial Agreement Delays and How to Defeat Them.
 
Débora is speaking at the Clinical Trial Forecasting, Budgeting and Contracting conference, part of SCOPE Summit, taking place February 12-15, 2018 in Orlando, FL. For more details, please visit: http://www.SCOPESummit.com

SCOPE 2018 | Clinical Trial Contracting Challenges

Dr. John Haurum shares his perspective on the future of bispecific antibodies in the next 5 years, common myths about immune system activation using bispecifics and some novel compounds inside and outside of IO fields that he’s looking forward to the most at the Bispecific Antibody Pipeline Congress.

For more information, please visit http://www.BispecificAntibodyCongress.com/Bispecific-Antibody-Clinical-Relevance

Bispecific Antibody Pipeline Congress 2018 | Checkpoint-binding Bispecific Antibodies

A re-upload of a podcast with Marc Berger, M.D., Vice President, Real World Data & Analytics, Pfizer

Population Segmentation and Care Management in R&D of New Therapeutics

A re-upload of a podcast with Brian Dixon, MPA, Ph.D., FHIMSS, Assistant Professor, Health Informatics, Indiana University; Research Scientist, Regenstrief Institute; Investigator in Residence, Department of Veterans Affairs

Leveraging Health Information Exchange to Achieve Population Health Surveillance

A re-upload of a podcast with Sandy Aronson, Executive Director, IT, Partners HealthCare Center for Personalized Genetic Medicine

Information Technology in Support of Genetics in the Clinic

Dr. Bradley Perkins develops a digital platform that can estimate personalized ten year mortality risk. In this podcast, he shares with us what this platform is and how it works to protect and improve the health of individuals and families. In the era of personalized medicine, Dr. Perkins explains what the necessary steps to bring this platform to the general public, gives us other personalized medicine examples and how it will affect the cost of medical care.

For more information, please visit http://www.TriConference.com/Precision-Medicine

Molecular Med Tri-Con 2019 | Personalized Estimation of Motality Risk

For decades, high-performance computing (HPC) has played a crucial role in advancing healthcare. Enabled by techniques like next-generation sequencing (NGS), modern computer systems have helped us understand the biology of disease and helped facilitate the development of newer more effective drugs. While once deployed mainly in research, today HPC is edging ever closer to front-line clinical care supporting advanced diagnostics, genetic counseling, and personalized medicine. 

While core bioinformatics applications aren’t going anywhere, modern medicine is increasingly a big data problem as well. Determining the optimal treatment depends on collaboration, the fusion of genetic data with other rich datasets like MRIs, ultrasound images, and population level studies. Increasingly analytics and AI techniques like machine learning are helping healthcare providers sift through massive amounts of data to make better decisions for patients more quickly and efficiently.

For IT organizations, providing a foundation to support this rapid innovation has been challenging. With the need for increasingly specialized hardware, new application frameworks, cost challenges, and the need to share data as never before, institutions are increasingly embracing cloud computing. Univa has played a key role in helping life sciences companies manage diverse workloads on HPC clusters both on-premises and in the cloud. In this Podcast, Univa will discuss how workloads are evolving, share some of the pressures faced by their life-sciences customers, and discuss practical approaches to modernizing IT environments to support the increased variety of applications in the life sciences software ecosystem.

Bio-IT World | Advancing Life Sciences Research: Accelerating innovation in the age of cloud

Dr. Jennifer Chadwick shares her journey from academia to industry, and the best advice that got her to where she is today.

PEGS Boston 2019 | Jennifer Chadwick’s Story of Building a Creative and Authentic Career in Science

Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process.

For more information, please visit https://www.triconference.com/Companion-Diagnostics

Molecular Med Tri-Con 2019 | Target the Tumor Mutational Burden and Pursue Harmonization

Harry Glorikian interviews Niven R. Narain about his approach on how to add more precision to the process of drug development and diagnostic development while engage more reproducibility. Niven also discusses how to use the biomarkers not only as a readout but as a vehicle and an agent to design clinical trials much differently.

For more information, please visit https://www.TriConference.com/Precision-Medicine

Molecular Med Tri-Con 2019 | Real Precision Medicine is Starting with the Patient

Dr. Richard Levenson discusses the role of AI in digital pathology – what works, and what needs to be done for AI to reach its full potential.

For more information, please visit https://www.TriConference.com/Digital-Pathology

Molecular Med Tri-Con 2019 | Putting the AI in Wait

Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research.

For more information, please visit https://www.MolecularDXEurope.com/Point-of-Care-Dx

Molecular DX Europe 2019 | Using Point-of-Care Diagnostics to Advance a One Health Approach

Samuel Levy of Bluestar Genomics speaks to CHI on March 13, 2019. Dr. Levy will be speaking during The Liquid Biopsy Summit, June 17-19, in San Francisco, CA.
 
Topics include cell-free diagnostics in precision medicine, transformation & growth in the liquid biopsy field, epigenomic assays for cancer detection, and opportunities ahead.

For more information, please visit https://www.LiquidBiopsySummit.com/Programs

the Liquid Biopsy Summit 2019 | Reimagining Liquid Biopsy Applications with Epigenomics

Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health.

For more information, please visit https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics

Next Generation Dx 2019 | Launch a Paradigm Shift through an Innovative Diagnostic Test

Nancy Sajjadi, an independent bioassay quality consultant with over 30 years of experience in biopharmaceutical product development, discusses her history in the bioassay field and how her experience has fostered her passion for teaching biostatistics to non-statisticians with CHI.
 
Topics include: challenges in developing bioassays for cell & gene therapies, regulatory considerations and standards for bioassays, fostering collaboration between statisticians and bench scientists, and more

For more information, please visit https://www.ImmunogenicitySummit.com/Workshop

Immunogenicity Summit 2019 | From Cell & Gene Therapy to Biostatistics

Gene therapy presents a promising path ahead for patients of rare diseases. The United States Food and Drug Administration’s Director of the Center for Biologics Evaluation and Research, Dr. Peter Marks discusses his work advancing production and availability of gene therapies for rare disorders, and the unique challenges to producing efficacious therapeutics in this field.

For more information, please visit https://www.TriConference.com/Gene-Therapy

Molecular Med TriCon 2019 | Gene Therapy for Rare Disorders

Prof. Matthew Lungren shares his stories on how he got to where he is now and where his artificial intelligent inspiration for medicine comes from. He also talks about many great collaborations at the Stanford Center in precision medicine and what he’s looking to see more in this field in the next 5 years. 

For more information, please visit https://www.TriConference.com/Precision-Medicine

Molecular Med Tri-Con 2020 | Artificial Intelligence in Precision Medicine

The CHI Podcasts are produced by the Cambridge Healthtech Institute and offer in-depth interviews with research and business leaders from many facets of biotechnology.

Popular tracks by CHI Podcasts